Additional Tracer Injection to Improve the Technical Success Rate of Lymphoscintigraphy for Sentinel Node Biopsy in Breast Cancer by unknown
ORIGINAL ARTICLE – BREAST ONCOLOGY
Additional Tracer Injection to Improve the Technical Success
Rate of Lymphoscintigraphy for Sentinel Node Biopsy in Breast
Cancer
E. M. Heuts, MD1, F. W. C. van der Ent, PhD2, H. A. G. van der Pol, MD3, M. F. von Meyenfeldt, PhD1,
and A. C. Voogd, PhD4
1Department of Surgery, University Hospital Maastricht, Maastricht, The Netherlands; 2Department of Surgery, Orbis
Medical Center, Sittard, The Netherlands; 3Department of Nuclear Medicine, Orbis Medical Center, Sittard, The
Netherlands; 4Department of Epidemiology, Maastricht University, Maastricht, The Netherlands
ABSTRACT
Background. Sentinel node (SN) biopsy has become the
standard of care in the treatment of breast cancer. The aim
of this study is to determine the value of additional tracer
injection to increase the technical success rate of the SN
procedure and to identify factors that influence the ability
to visualize hotspots.
Methods. From February 1997 to August 2007, 1,208
clinically node-negative breast cancer patients underwent
lymphatic mapping for SN biopsy. The technique involved
the injection of 370 MBq (10 mCi) Tc-99 m-nanocolloid
peritumorally. In case of insufficient or absent visualization
of hotspots 37 MBq (1 mCi) of additional tracer was given
intracutaneously above the tumor.
Results. In 93 patients (7.7%) visualization of hotspots on
initial lymphoscintigraphy was insufficient (41 patients) or
absent (52 patients). The first 14 patients did not receive
additional tracer injection. In five patients, additional tracer
did not result in successful lymphoscintigraphy, which is
correlated with massive nodal tumor infiltration. In 33
patients with negative initial lymphoscintigraphy, addi-
tional tracer injection resulted in secondary SN
visualization. In 41 patients with faint hotspots on initial
lymphoscintigraphy, additional tracer injection, by
increasing nodal uptake, simplified accurate SN biopsy.
Decreased radiotracer uptake in this group was associated
with older age and high body mass index (BMI).
Conclusions. Additional tracer injection following initial
scan failure increases the success rate of lymphoscintigra-
phy during lymphatic mapping in breast cancer, without
compromising accuracy. If additional tracer injection does
not result in secondary SN visualization, gross nodal tumor
involvement is often present and axillary lymph node dis-
section (ALND) is mandatory.
Since the introduction of the sentinel node (SN) proce-
dure in breast cancer, many validation studies have
confirmed the accuracy of the SN biopsy in predicting
axillary node status.1–6 As compared with axillary lymph
node dissection (ALND), SN biopsy causes less morbidity
and provides the same staging information. As a conse-
quence, ALND is nowadays abandoned in case of a
negative SN biopsy, thereby avoiding unnecessary mor-
bidity and costs associated with ALND.
However, sometimes the lymphatic mapping procedure
fails because of insufficient or absent radioactive tracer
uptake in the lymph nodes. Because a negative preopera-
tive lymphoscintigraphy is predictive for failure of
intraoperative SN identification, faint or nonvisualization
of hotspots on lymphoscintigraphy (initial scan failure)
frequently results in the need to perform ALND.7
After having experienced 14 patients with a negative
preoperative lymphoscintigraphy in the first 3 years of our
study, we started to use additional radiocolloid tracer
injections as of May 2000, to avoid technical failure of the
lymphatic mapping procedure.
The aim of this study is to determine the value of
additional tracer injection to increase the technical success
rate of the sentinel node procedure in case of a vague or
negative lymphoscintigraphy and to identify factors that
influence nonvisualization of hotspots.
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PATIENTS AND METHODS
From April 1997 to August 2007, after having received
approval of the Local Ethical Committee, and after
informed consent, a total of 1,208 consecutive patients with
clinically node-negative operable primary breast cancer
were included in a prospective study on SN biopsy. In
phase I of this study (137 patients) SN biopsy was followed
by completion axillary lymph node dissection in all cases.
In phase II, after validation of the SN technique in our
institute, completion axillary lymph node dissection was
performed only in cases of tumor-positive axillary SN or
unsuccessful SN procedure. From this ongoing prospective
study we analyzed all consecutive patients who showed
inadequate or absent visualization of hotspots on the initial
lymphoscintigraphic images (Figs. 1–3).
Our technique of SN biopsy has been described in detail
elsewhere.2 The lymphatic mapping procedure consists of
370 MBq (10 mCi) TC-99 m-nanocolloid injected peritu-
morally or in the breast parenchyma surrounding the cavity
of a previous excisional biopsy. All patients underwent
preoperative lymphoscintigraphy following a mean interval
of 16 h (range 12–18 h). In case of initial scan failure,
additional radiocolloid tracer injections of 37 MBq
(1 mCi) Tc-99 m-nanocolloid intracutaneously above the
tumor were used as of May 2000, in order to increase the
technical success rate of lymphoscintigraphy by obtaining
secondary SN visualization. A second lymphoscintigraphy
was performed 10–15 min after the additional tracer
injection was given.
In relation to the mapping procedure, radiation exposure
guidelines and doses were considered for both patients and
personnel and were found to be well within legal safety
limits, as published previously.2
In 2002 preoperative ultrasonography of the axilla was
introduced in our hospital and became standard procedure
in combination with fine-needle aspiration (FNA) cytology
in case of clinically or radiologically suspicious axillary
lymph nodes. Thus, patients treated before 2002 did not
receive routine ultrasound investigation of the axilla.
During surgery, all axillary and nonaxillary SNs were
pursued, as visualized by lymphoscintigraphy. Intraopera-
tive identification of the SNs was based both on blue dye
mapping and gamma probe detection. In all cases of a
failed SN procedure, whether based on secondary scan
failure or based on intraoperative SN identification failure,
ALND was performed, which involved at least removal of
all level I and II lymph nodes.
Histopathologic examination of the SN consisted of
routine serial sectioning with hematoxylin and eosin
(H&E) staining, followed by immunohistochemical (IHC)
staining, whenever routine H&E staining did not reveal
metastases.
Depending on the type of variable, chi-squared test or t-
test was used to compare the characteristics of patients with
successful lymphoscintigraphy and with initial scan failure.
RESULTS
In all, 1,208 consecutive patients with clinically node-
negative breast cancer were included in this study. Patient
and tumor characteristics are listed in Table 1.
Initial Scan Failure
In 93 patients, the results of preoperative lymphoscin-
tigraphy were classified as initial scan failure: in 52
FIG. 1 Lymphoscintigraphy of patient with initial scan failure (a)
and secondary scan failure after additional tracer injection (b)
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patients, because lymphoscintigraphy showed no axillary
hotspots at all (negative lymphoscintigraphy), and in 41
patients because the initial SN visualization was considered
inadequate (i.e., too faint to allow successful intraoperative
SN retrieval). The mean age of these 93 patients was
65.8 years, compared with 58.5 years for the remaining
group of 1,115 patients with clear hotspots on initial
lymphoscintigraphy (p \ 0.0001).
Within the first 3 years of the study 14 patients (group
A, Table 2) with negative initial lymphoscintigraphy did
not receive additional tracer injection and consequently
ALND was performed in all cases. Of these 14 patients, 10
were found to have positive lymph nodes, with 5 of them
having more than ten involved nodes. The remaining four
patients had a negative SN procedure, using the blue dye
technique, which was confirmed by completion ALND. No
axillary recurrences were seen in these four patients within
a median follow-up of 80 months.
As of May 2000, in case of initial scan failure, an
additional tracer injection of 1 mCi Tc-99 m-nanocolloid
intracutaneously was routinely used.
Secondary Scan Failure
In five patients (group B, Table 2) with initial scan
failure, following additional tracer injection, repeated
FIG. 3 Lymphoscintigraphy of patient with faint hotspot (a), but
clear hotspot after additional tracer injection (b)
FIG. 2 Lymphoscintigraphy of patient with initial scan failure (a),
but secondary SN visualization after additional tracer injection (b)
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lymphoscintigraphy still did not show hotspots (Fig. 1a, b).
Mean age of these patients was 66.2 years. Successful SN
harvesting was possible in only one patient, because a
(tumor-positive) palpable lymph node was found
intraoperatively.
Axillary dissection was done in all five patients and
showed a tumor-positive axilla in four (80%), of whom
three patients showed massive tumor infiltration of almost
all axillary lymph nodes. The only node-negative patient in
this subgroup had no axillary recurrence during a follow-up
period of 49 months.
Secondary SN Visualization
In 33 patients (group C, Table 2) with initial scan fail-
ure, we noted secondary SN visualization on repeated
lymphoscintigraphy as a direct result of additional tracer
injection (Fig. 2a, b). In these patients mean age was
64.7 years. Secondary lymphoscintigraphy clearly showed
one or more axillary hotspots, which subsequently could be
harvested in all cases, showing a positive SN in 17 patients
(52%), all of whom underwent ALND. Massive nodal
tumor burden, with ten or more tumor-positive nodes, was
TABLE 1 Comparison of
characteristics of patients
(N = 1208) with successful
lymphoscintigraphy and with
initial scan failure
DCIS ductal carcinoma in situ
a Sample of 100 patients






N % n %
Age (years) \0.0001
B50 346 31 10 11
51–70 544 49 52 56
[70 225 20 31 33
Tumor localization 0.23
Lateral 615 55 43 46
Medial 395 36 40 43
Central 105 9 10 11
Tumor size \0.0001
DCIS/Paget 37 3 1 1
T1 653 59 46 49
T2 398 36 34 37
T3 27 2 12 13
Number of positive lymph nodes \0.0001
0 676 61 46 49
1–3 351 31 24 26
[3 88 8 23 25
Tumor grade 0.43
Good 286 26 29 31
Moderate 478 43 39 42
Poor 351 31 25 27
Surgery 0.84
Core biopsy 932 84 77 83
Previous excisional biopsy 183 16 16 17
Estrogen receptor status 0.80
Negative 215 21 19 22
Positive 823 79 68 78
Missing values 77 6
Progesterone receptor 0.14
Negative 367 35 24 28
Positive 670 65 63 72
Missing values 78 6
IM hotspots on lymphoscintigraphy 236 21 5 5 \0.0001
BMI 100a 25.5b 93 29.0b \0.0001
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present in three patients only (9%). In 15 patients the SN
was found to be tumor-negative and no ALND was per-
formed. No axillary recurrences were noted during a
median follow-up of 27 months in these patients. One
patient (5.5%, 1/18) in this subgroup had a false-negative
SN procedure. A tumor-positive lymph node was found
during subsequent simple mastectomy. She was given
axillary radiotherapy. No axillary recurrence was seen
thereafter within a 60-month follow-up period.
Enhanced Lymphoscintigraphy
In 41 patients (group D, Table 2) with initial scan fail-
ure, in which initial lymphoscintigraphy showed only a
faint hotspot, judged to be insufficient to allow successful
SN harvesting, additional tracer injection led to increased
radioactive uptake in the same hotspot (Fig. 3a, b), rather
than visualizing additional hotspots. The mean age of these
patients was 67.0 years. Additional hotspots as a result of
additional tracer injection were seen in only five patients
(12%). The increased radioactive uptake facilitated SN
harvesting, which was successful in all cases. A tumor-
positive SN was found in 16 patients (39%), which was not
different from the group of 1,115 patients with clear hot-
spots on initial lymphoscintigraphy (39%). Only one
patient (2.4%) had massive tumor infiltration in the axilla,
showing all axillary lymph nodes to be tumor-positive. No
completion ALND was performed in the remaining 25
patients with a negative SN biopsy. Among these 25
patients again no axillary recurrences were found during a
median follow-up of 41 months.
DISCUSSION
Because of its high sensitivity to detect nodal metastatic
disease and its minimally invasive nature, SN biopsy has
become the standard of care for staging early invasive
breast cancer, thereby limiting axillary dissection to
patients with axillary metastases and sparing node-negative
patients the morbidity of axillary dissection. However,
sometimes the lymphatic mapping procedure tends to fail,
because of inadequate or even absent radioisotope uptake
in the SN. This urges the surgeon to perform a complete
axillary lymph node dissection, which might have been
avoided had the lymphatic mapping been successful.
After having experienced 14 patients with a negative
preoperative lymphoscintigraphy in the first 3 years of our
study, we started to use additional radiocolloid tracer
injections as of May 2000, to avoid technical failure of the
lymphatic mapping procedure. The use of additional tracer
injection has been previously reported by Cserni et al. in 20
patients.8
Several factors have been identified to influence lym-
phatic mapping. Besides technical factors, such as tracer
volume, tracer dose, site of tracer injection, and timing of
lymphoscintigraphic imaging, other factors such as prior
breast surgery and upper lateral tumor location, which
might hamper lymphatic mapping due to shine through,
have been reported to influence lymphatic drainage pat-
terns. However, there are three major reasons for initial
scan failure: extensive nodal tumor infiltration, increased
age, and increased body mass index (BMI).
Extensive Nodal Tumor Infiltration
Axillary hotspot visualization is negatively influenced by
extensive nodal involvement.2,9–14 This can be explained by
nodal tracer uptake physiology: the radioactive tracer is
bound to colloid, which is phagocytosed by macrophages
within the normal lymph tissue of the SN. If the SN, or the
afferent lymph tracts, show massive tumor infiltration and/
or extranodal growth, the lymph flow might be blocked, or
TABLE 2 Patient and tumor characteristics of patients with initial scan failure (N = 93)
A B C D p-value
Number of patients 14 5 33 41
Age (mean in years) 64.7 66.2 64.7 67.0
BMI (mean in kg/m2) 29.3 29.1 28.9 28.9
Tumor size [2 cm 9 (64%) 5 (100%) 15 (45%) 17 (41%) 0.06
Ultrasound axilla (n) 1 (7%) 2 (40%) 17 (52%) 23 (56%) 0.007
Axillary metastases (%) 10 (71%) 4 (80%) 17 (52%) 16 (39%) 0.10
Massive nodal/lymphatic tract infiltration 8 (57%) 3 (60%) 3 (9%) 1 (2%) \0.0001
Axillary recurrence in node-negative patients – – 0 0
Median follow-up node-negative patients (months) 80a 49a 27 41
Group A: initial scan failure, no additional tracer given; group B: initial and secondary scan failure; group C: initial scan failure, successful
secondary scan; group D: enhanced scan after additional tracer injection
a Node-negativity confirmed with ALND
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there might not be enough functional lymph tissue left to
phagocytose the radiocolloid. Thus, if a SN is completely
replaced by tumor or the afferent lymph tract is blocked by
extensive lymphatic tract infiltration, initial lymphoscin-
tigraphy can fail to show any hotspot. Additional tracer
injection under these circumstances might result in sec-
ondary scan failure, in which case ALND is mandatory.
Lymphatic tumor burden does not seem to affect blue
dye uptake because, in contrast to the uptake of radiocol-
loid, which is based on sufficient functional lymph tissue,
blue dye uptake is a process of passive diffusion through
the lymphatic system.11
Massive nodal tumor and/or lymphatic tract infiltration
was present in 57.1% of 14 patients (group A) early in our
study, in which a negative initial lymphoscintigraphy was
not followed by additional tracer injection, and in 60% of 5
patients (group B), in whom additional tracer injection,
after initial scan failure, did not result in secondary SN
visualization.
If additional tracer injection does result in secondary SN
visualization, as was seen in 33 patients (group C) in our
study, it can be argued whether this visualized hotspot is in
fact the true SN, or might be an alternative lymph node
which, based on rerouting of lymph flow, is erroneously
considered to be the true SN.13,15,16 If so, rerouting of
lymph flow during lymphatic mapping would ultimately
result in increased false-negative rates.17
However, of 33 patients with secondary SN visualization
resulting from additional tracer injection, only 1 patient
(5.5%) had a false-negative SN biopsy, whereas 15 patients
with a negative SN after additional tracer injection, who
consequently had no ALND, showed no axillary recurrences
within 29 months of follow-up. These results suggest that
SN biopsy after additional tracer injection does not com-
promise its accuracy, as was also pointed out by others.18
Internal Mammary (IM) Basin Drainage
The incidence of IM metastasis is correlated with axil-
lary nodal involvement.19 It seems intuitive that a large
axillary tumor burden can result in blockage of lymph flow
to the axilla, consequently leading to redirection of lymph
flow to the IM chain.13 However our results, like those of
other investigators, show that extensive nodal infiltration of
the axilla is not correlated with increased lymph drainage
to the IM lymph nodes, since IM hotspots were noted in
only 5.4% (5/93) of patients with initial scan failure, versus
21.2% in patients with a successful initial lymphoscintig-
raphy (Table 1).11 This seemingly unexpected result is
probably explained by the fact that patients with initial
scan failure had a significantly higher mean age and BMI,
both of which are inversely correlated to IM lymph
drainage.
Palpable Lymph Nodes
An axillary lymph node with gross tumor involvement
might consequently be enlarged, and thus is more likely to
be detected by routine physical examination and/or axillary
ultrasound.
However, because a tumor-loaded lymph node also can
be the same size as a tumor-negative lymph node, physical
examination of the axillary lymph nodes in order to detect
nodal metastases has been shown to be inaccurate.20,21
Lymph nodes that can be palpated intraoperatively through
the incision of the SN biopsy and are felt to be suspicious
should be harvested and regarded as SN.2,22,23
Axillary Ultrasound
Routine preoperative axillary ultrasound is advocated by
several investigators.9,20,24 Combined with ultrasound-
guided FNA of enlarged or suspicious lymph nodes, pre-
operative ultrasound can detect metastatic disease, hence
avoiding an unnecessary or potentially unsuccessful SN
biopsy.
In this study, routine preoperative ultrasonography of the
axilla, which was introduced in our institute in 2002, was
performed in only 43 of the 93 patients with initial scan
failure. Moreover, of 48 patients with a tumor-positive axilla
in this subgroup, only 15 patients had a preoperative ultra-
sound examination of the axilla. In one of these patients,
ultrasound showed a suspicious lymph node, which was
tumor-negative on FNA. Among 15 patients who showed
extensive nodal involvement or extranodal tract invasion in
relation to initial scan failure (Table 2), preoperative axillary
ultrasound was performed in only two patients.
Thus, within this study we were not able to define the
diagnostic yield of preoperative axillary ultrasound in
relation to initial scan failure.
However, in retrospect, it seems clear that a substantial
number of our patients with initial scan failure would not
have needed a lymphatic mapping procedure had routine
preoperative axillary ultrasonography been introduced
earlier in our institute.
Increased Age
With the loss of estrogen levels in postmenopausal
women, the breast parenchyma is partially replaced by
fatty tissue. This process of fatty degeneration results in a
substantial decrease of lymphatic capillaries, normally
confined to the breast parenchyma, which in turn is cor-
related with decreased radioactive uptake in the SN. Thus,
increased age is inversely correlated with the ability to
visualize axillary hotspots and internal mammary
hotspots.13,25–29
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Likewise, our study showed that the mean age of patients
with initial scan failure was significantly higher when
compared with patients with a successful initial lympho-
scintigraphy (65.8 years versus 58.5 years, p \ 0.0001).
The inverse effect of increased age on the technical
success rate of lymphoscintigraphy becomes even more
obvious when looking at the results of 41 patients (group
D) in our study with initial scan failure showing only very
faint hotspots (Fig. 3), necessitating additional tracer
injection for successful SN retrieval. In this subgroup
massive nodal tumor infiltration was nearly absent (one
patient) and therefore no causal factor for initial scan
failure. Subsequently, the increased age in this subgroup
(mean 67 years)is the main factor, besides BMI, account-
able for non-visualization of hotspots (Table 2).
Body Mass Index (BMI)
BMI is also recognized as a factor that affects lym-
phoscintigraphic visualization of sentinel nodes.26,27,30 As
is true for increased age, patients with high BMI might
have sparse lymphatic capillaries and more fatty tissue in
their breast parenchyma.
In our study, mean BMI was 29.0 kg/m2 for the patients
with initial scan failure and 25.5 kg/m2 for a random
sample of 100 patients with clearly visible hotspots on the
initial scan. The difference was highly significant
(p \ 0.0001). This result confirms the findings from other
investigators regarding the effect of BMI on the success
rate of lymphoscintigraphy.
Previous Excisional Biopsy
Previous excisional biopsy is reported to result in
change of lymphatic drainage patterns and scan fail-
ure.4,13,31,32 In a previous study, we reported the results of
88 patients, in which SN biopsy with completion ALND
was performed following previous excisional biopsy.33
Initial scan failure was seen in only four patients (4.5%)
and no false-negative SN procedures were noted. In the
present study 199 patients had a previous excisional
biopsy. Of these, 8.0% showed initial scan failure as
compared with 7.6% in patients in whom breast cancer was
diagnosed by core biopsy (Table 1). Therefore, in our
opinion, excisional biopsy prior to SN biopsy is not cor-
related with scan failure.
CONCLUSION
Sentinel node (SN) biopsy has become the standard of
care in the treatment of breast cancer. To prevent unneces-
sary ALND, the results of preoperative lymphoscintigraphy
should be optimal. To avoid technical failure of lymphatic
mapping, we evaluated the results and accuracy of additional
intracutaneous radiocolloid tracer injections of 37 MBq
(1 mCi) in patients with initial scan failure. A negative initial
lymphoscintigraphy, if followed by additional tracer injec-
tion, resulted in secondary SN visualization in 87% of these
patients, thus enabling accurate (false-negative rate 5.5%)
SN biopsy. Both age and extensive nodal tumor infiltration as
well as BMI adversely affect SN visualization.
In case additional tracer injection does not result in
(secondary) SN visualization, ALND is mandatory,
because of the high risk of positive lymph nodes, many
times with massive tumor infiltration of the axilla.
If initial SN visualization is faint, this is mainly corre-
lated with increased age and high BMI, rather than large
tumor burden. In these patients additional tracer injection
facilitates an accurate SN procedure.
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